In this phase II randomized study , untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF ( docetaxel 75 mg/m2 , cisplatin 75 mg/m2 on day 1 , and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5 ) or DC ( docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1 ) every 3 weeks .
